Rolph Timothy

Rolph Timothy, Chief Scientific Officer at Akero Therapeutics (AKRO), has demonstrated a clear selling bias in recent months, with all five of his latest transactions involving disposals of company stock. Since September 2025, Timothy has executed multiple sales totaling approximately $1.16 million, including a $550,611 transaction on September 8 and a $527,447 sale on October 7. These disposals were partially offset by smaller acquisitions totaling $171,720 through market purchases coded as "M" transactions in November 2025, including a $274,059 purchase on November 25. However, the overall trend shows a net reduction in Timothy's AKRO holdings, with total sales of $2.41 million outweighing purchases of $1.72 million across his 36 reported transactions. The most recent filings show a shift toward derivative transactions coded as "D" in December 2025, though these carried no reported dollar value. Prior to this, Timothy's activity was concentrated in direct market transactions, with the November purchases representing his only recent acquisitions amid a broader pattern of disposals. All transactions involve AKRO shares exclusively, indicating Timothy maintains his exposure solely to his employer's stock. The absence of any purchases since late November, coupled with the December derivative filings, suggests a potential change in his approach to managing his AKRO position heading into 2026.